# US 2019/0054175 A1 · Excipient compounds for protein processing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0054175 A1
- Document ID: US20190054175A1
- Status: Published application
- Kind: A1
- Application number: 15/896,374
- Filed: 2018-02-14
- Published: 2019-02-21
- Earliest claimed: 2014-06-20
- Assignees: Reform Biologics, LLC
- Applicants: Reform Biologics, LLC
- Inventors: David S. Soane; Philip Wuthrich; Robert P. Mahoney; Mark Moody; Daniel G. Greene; Neil L. Schauer
- Web page: https://patentgrep.com/patent/US20190054175A1

## CPC

- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/385: {Serum albumin}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/32: against translation products of oncogenes
- C12N 9/2462: {Lysozyme (3.2.1.17)}
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12Y 302/01017: Lysozyme (3.2.1.17)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Disclosed herein are methods for improving a parameter of a protein-related process comprising providing a viscosity-reducing excipient compound selected from the group consisting of hindered amines, anionic aromatics, functionalized amino acids, oligopeptides, short-chain organic acids, and low molecular weight aliphatic polyacids, and adding a viscosity-reducing amount of the viscosity-reducing excipient compound to a carrier solution for the protein-related process, wherein the carrier solution contains a protein of interest, and carrier solutions comprising a liquid medium in which is dissolved a protein of interest, and a viscosity-reducing excipient, wherein the viscosity of the carrier solution has a lower viscosity that that of a control solution that is substantially similar to the carrier solution except for the presence of the viscosity-reducing excipient.

## Claims

### Claim 1

A method of improving a parameter of a protein-related process, comprising:
providing a viscosity-reducing excipient additive comprising at least one excipient compound selected from the group consisting of hindered amines, anionic aromatics, functionalized amino acids, oligopeptides, short-chain organic acids, low molecular weight aliphatic polyacids, and diones and sulfones, and
adding a viscosity-reducing amount of the at least one excipient compound to a carrier solution for the protein-related process, wherein the carrier solution contains a protein of interest,
thereby improving the parameter.

### Claim 2 (depends on 1)

The method of claim 1, wherein the parameter is selected from the group consisting of cost of protein production, amount of protein production, rate of protein production, and efficiency of protein production.

### Claim 3 (depends on 1)

The method of claim 1, wherein the parameter is a proxy parameter.

### Claim 4 (depends on 1)

The method of claim 1, wherein the protein-related process is an upstream processing process.

### Claim 5 (depends on 4)

The method of claim 4, wherein the carrier solution for the upstream processing process is a cell culture medium.

### Claim 6 (depends on 5)

The method of claim 5, wherein the step of adding the excipient additive to the carrier solution comprises a first substep of adding the excipient additive to a supplemental medium to form an excipient-containing supplemental medium, and a second substep of adding the excipient-containing supplemental medium to the cell culture medium.

### Claim 7 (depends on 1)

The method of claim 1, wherein the protein-related process is a downstream processing process.

### Claim 8 (depends on 7)

The method of claim 7, wherein the downstream processing process is a chromatography process.

### Claim 9 (depends on 8)

The method of claim 8, wherein the chromatography process is a Protein-A chromatography process.

### Claim 10 (depends on 8)

The method of claim 8, wherein the chromatography process recovers the protein of interest, and wherein the protein of interest is characterized by an improved protein-related parameter selected from the group consisting of improved purity, improved yield, fewer particles, less misfolding, or less aggregation, as compared to a control solution.

### Claim 11 (depends on 10)

The method of claim 10, wherein the improved protein-related parameter is improved yield of the protein of interest from the chromatography process.

### Claim 12 (depends on 1)

The method of claim 1, wherein the protein-related process is a process selected from the group consisting of filtration, injection, syringing, pumping, mixing, centrifugation, membrane separation, and lyophilization.

### Claim 13 (depends on 12)

The method of claim 12, wherein the process requires less force than a control process.

### Claim 14 (depends on 1)

The method of claim 1, wherein the protein-related process is selected from the group consisting of a cell culture process, a cell culture harvesting process, a chromatography process, a viral inactivation process, and a filtration process.

### Claim 15 (depends on 14)

The method of claim 14, wherein the protein-related process is the viral inactivation process, and the viral inactivation process is conducted at a pH level of about 2.5 to about 5.0.

### Claim 16 (depends on 15)

The method of claim 15, wherein the protein-related process is the viral inactivation process, and the viral inactivation process is conducted at a higher pH than the control process.

### Claim 17 (depends on 14)

The method of claim 14, wherein the protein-related process is the filtration process.

### Claim 18 (depends on 17)

The method of claim 17, wherein the filtration process is a virus removal filtration process or an ultrafiltration/diafiltration process.

### Claim 19 (depends on 17)

The method of claim 17, wherein the filtration process is characterized by an improved filtration-related parameter.

### Claim 20 (depends on 19)

The method of claim 19, wherein the improved filtration-related parameter is a faster filtration rate than the filtration rate of the control solution.

### Claim 21 (depends on 19)

The method of claim 19, wherein the improved filtration-related parameter is production of a smaller amount of aggregated protein than the amount of aggregated protein produced by a control filtration process.

### Claim 22 (depends on 19)

The method of claim 19, wherein the improved filtration-related parameter is a higher mass transfer efficiency than the mass transfer efficiency of the control filtration process.

### Claim 23 (depends on 19)

The method of claim 19, wherein the improved filtration-related parameter is a higher concentration or a higher yield of the target protein than a concentration or yield of the target protein produced by the control filtration process.

### Claim 24 (depends on 1)

The method of claim 1, wherein the viscosity-reducing excipient additive comprises two or more excipient compounds.

### Claim 25 (depends on 1)

The method of claim 1, wherein the at least one excipient compound is a hindered amine.

### Claim 26 (depends on 25)

The method of claim 25, wherein the at least one excipient compound is selected from the group consisting of caffeine, saccharin, acesulfame potassium, aspartame, theophylline, taurine, 1-methyl-2-pyrrolidone, 2-pyrrolidinone, niacinamide, and imidazole.

### Claim 27 (depends on 26)

The method of claim 26, wherein the at least one excipient compound is selected from the group consisting of caffeine, taurine, niacinamide, and imidazole.

### Claim 28 (depends on 1)

The method of claim 1, wherein the at least one excipient compound is an anionic aromatic excipient.

### Claim 29 (depends on 28)

The method of claim 28, wherein the anionic aromatic excipient is 4-hydroxybenzenesulfonic acid.

### Claim 30 (depends on 1)

The method of claim 1, wherein the viscosity-reducing amount is between about 1 mg/mL to about 100 mg/mL of the at least one excipient compound.

### Claim 31 (depends on 1)

The method of claim 1, wherein the viscosity-reducing amount is between about 1 mM to about 400 mM of the at least one excipient compound.

### Claim 32 (depends on 31)

The method of claim 31, wherein the viscosity-reducing amount is an amount from about 2 mM to about 150 mM.

### Claim 33 (depends on 1)

The method of claim 1, wherein the carrier solution comprises an additional agent selected from the group consisting of preservatives, sugars, polysaccharides, arginine, proline, surfactants, stabilizers, and buffers.

### Claim 34 (depends on 1)

The method of claim 1, wherein the protein of interest is a therapeutic protein.

### Claim 35 (depends on 34)

The method of claim 34, wherein the therapeutic protein is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, an antibody fragment, a fusion protein, a PEGylated protein, an antibody-drug conjugate, a synthetic polypeptide, a protein fragment, a lipoprotein, an enzyme, and a structural peptide.

### Claim 36 (depends on 34)

The method of claim 34, wherein the therapeutic protein is a recombinant protein.

### Claim 37 (depends on 1)

The method of claim 1, further comprising a step of adding a second viscosity-reducing excipient to the carrier solution, wherein the step of adding the second viscosity-reducing compound adds an additional improvement to the parameter.

### Claim 38

A carrier solution comprising:
a liquid medium in which is dissolved a protein of interest, and a viscosity-reducing additive, wherein the carrier solution has a lower viscosity that that of a control solution.

### Claim 39 (depends on 38)

The carrier solution of claim 38, wherein the carrier solution further comprises an additional agent selected from the group consisting of preservatives, sugars, polysaccharides, arginine, proline, surfactants, stabilizers, and buffers.
